Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    RG6382

    Other names: RG6382; RO7507062

    Modality: Bispecific Antibody

    Disease State: Systemic Lupus Erythematosus (SLE)

    Summary

    Anti-CD19xCD3 T-cell dependent bispecific antibody (TCB) is an investigational T cell-engaging bispecific antibody, designed to engage both cluster of differentiation 19 (CD) 19 on B cells and CD3 on T cells.1,2

    Clinical Trials

    CD19 x CD3
    NCT ID Study Phase Enrollment Status Study Title
    NCT05835986 Phase I Active, not recruiting A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus View details
    1. Roche. Product Development Portfolio. July 24, 2025. Accessed August 20, 2025. https://www.roche.com/​solutions/​pipeline
    2. Kollert F, Robertson S, Erpenbeck V, et al. Abstract No. 2436: characterization of RO7507062, a CD19-targeting T-cell bispecific antibody (CD19TCB), and design of its ongoing phase 1 trial in systemic lupus erythematosus. Abstract presented at: ACR Convergence 2024; November 14-19, 2024; Washington, DC. Accessed March 25, 2026. https://acrabstracts.org/​abstract/​characterization-of-ro7507062-a-cd19-targeting-t-cell-bispecific-antibody-cd19tcb-and-design-of-its-ongoing-phase-1-trial-in-systemic-lupus-erythematosus/

    Looking for more information?

    Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

    Connect with an MSL
    Submit a Request

    Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT

    TOP

    • CD
      Cluster of differentiation

    • SLE
      Systemic lupus erythematosus

    • TCB
      T-cell dependent bispecific antibody

    +